FIELD: biotechnology; medicine; pharmaceutics.
SUBSTANCE: present invention relates to biotechnology and pharmaceutics, namely to antibody conjugates for treating rheumatoid arthritis in a patient. Antibody included in these conjugates specifically binds Extra-Domain-A (ED-A) to fibronectin and is conjugated to interleukin-10. Present invention also discloses a nucleic acid encoding said conjugate, a host cell for its production, a pharmaceutical composition for treating rheumatoid arthritis in a patient, as well as a method of producing said conjugate and a method for treating rheumatoid arthritis, a method for delivering interleukin-10 to regions of rheumatoid arthritis and method diagnosis of rheumatoid arthritis in a patient with its use.
EFFECT: present invention provides successful treatment of rheumatoid arthritis by selective delivery of interleukin-10 to sites of disease localization.
35 cl, 8 dwg, 2 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIGENS ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE | 2012 |
|
RU2612878C2 |
| IL2 AND MUTANT TNF IMMUNOCONJUGATES | 2017 |
|
RU2758139C2 |
| ANTI-KIT ANTIBODIES AND USES THEREOF | 2013 |
|
RU2681730C2 |
| THERAPEUTIC DLL4-BINDING PROTEINS | 2010 |
|
RU2570639C2 |
| ANTI-CXCR4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | 2014 |
|
RU2675516C2 |
| BINDING MOLECULES SPECIFIC TO IL-21, AND FIELD OF APPLICATION THEREOF | 2015 |
|
RU2708336C2 |
| THERAPEUTIC ANTIBODIES AND THEIR APPLICATION | 2016 |
|
RU2722381C2 |
| SPECIFIC LINKING AGENTS AGAINST B7-H1 | 2010 |
|
RU2571204C2 |
| SPECIFIC BINDING AGENTS AGAINST B7-H1 | 2010 |
|
RU2706200C2 |
| INTERFERON ALPHA 1 RECEPTOR ANTIBODIES AND USE THEREOF | 2005 |
|
RU2600884C2 |
